Video

Initial Results of the Ongoing MYSTIC Trial in Stage IV Lung Cancer

David R. Gandara, MD, professor of Medicine, University of California Davis Comprehensive Cancer Center, discusses the initial results of the ongoing MYSTIC trial, which is exploring the combination of durvalumab (Imfinzi) and tremelimumab versus chemotherapy in stage IV lung cancer.

David R. Gandara, MD, professor of Medicine, University of California Davis Comprehensive Cancer Center, discusses the initial results of the ongoing MYSTIC trial, which is exploring the combination of durvalumab (Imfinzi) and tremelimumab versus chemotherapy in stage IV lung cancer.

Related Videos
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
Hope on the Horizon: 2 Food Allergy Breakthroughs in 2024
Nathan D. Wong, MD, PhD: Growing Role of Lp(a) in Cardiovascular Risk Assessment | Image Credit: UC Irvine
Discussing FDA Approval of Tapinarof Cream for Atopic Dermatitis, with John Browning, MD
Laurence Sperling, MD: Expanding Cardiologists' Role in Obesity Management  | Image Credit: Emory University
Laurence Sperling, MD: Multidisciplinary Strategies to Combat Obesity Epidemic | Image Credit: Emory University
Schafer Boeder, MD: Role of SGLT2 Inhibitors and GLP-1s in Type 1 Diabetes | Image Credit: UC San Diego
© 2024 MJH Life Sciences

All rights reserved.